Clinical trials should explore adjunctive use with existing therapies (e.g., metformin or GLP-1 agonists), leveraging these compounds’ unique capacity to concurrently target insulin signaling and inflammation—a combinatorial strategy poised to address diabetes-associated comorbidities more effectively than current monotherapies. Here, INS is linked to diabetes mellitus.